Xponance Inc. Sells 736 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Xponance Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 193,216 shares of the biopharmaceutical company’s stock after selling 736 shares during the period. Xponance Inc.’s holdings in Gilead Sciences were worth $17,847,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC increased its holdings in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $112.26 on Tuesday. The firm has a market capitalization of $139.80 billion, a P/E ratio of 303.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The business’s fifty day simple moving average is $102.24 and its 200 day simple moving average is $93.16. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.81%. Gilead Sciences’s payout ratio is 854.05%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GILD. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Piper Sandler upped their price objective on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Wells Fargo & Company upped their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $104.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.